Thyroid eye disease specialists react to the FDA approval of veligrotug-vvze

On June 26, 2026, the FDA approved veligrotug-vvze (Lumvoa; Viridian Therapeutics) for the treatment of thyroid eye disease (TED), regardless of disease activity or duration.^1,2 The approval was supported by results from two pivotal phase 3 trials—THRIVE, which enrolled patients with active TED, and THRIVE-2, which enrolled patients with chronic TED—both of which met their primary and all secondary end points at week 15.¹ Patients in both trials received 5 IV infusions administered every 3 weeks over a 12-week course, with proptosis reductions observed as early as week 3.¹ Veligrotug is the first approved therapy in the IGF-1R inhibitor class to carry labeling that includes data from both active and chronic TED, according to the company.¹ The approval expands the armamentarium of FDA-approved therapies for TED, joining teprotumumab (Tepezza; Amgen), which was approved in 2020 and recently reported positive phase 3 results for a subcutaneous formulation.³